

19 May 2014

Operational update and Extension of Closing Date

Operational Update

Resonance Health is pleased to announce it has signed a FerriScan contract with a major university hospital in Florida, USA. This will be the first FerriScan facility in the state of Florida which has a very high population of patients with sickle cell disease, many of whom have iron overload. Since January, Resonance has signed contracts with new customers in South Carolina (USA), Germany, the United Kingdom, Tunisia and Australia.

21 new radiology facilities have been set up for FerriScan imaging since the start of 2014 enabling more patients to gain access to FerriScan. This is the result of new commercial contracts signed with hospitals, the expanding use of FerriScan in clinical trials of iron overload and the establishment of additional FerriScan facilities participating in programs funded by third party pharmaceutical companies to assist patients on iron chelation therapy.

Resonance Health's large footprint around the globe provides an established network to introduce the HepaFat-Scan product. The company has received positive feedback from a number of clinicians that see value in the role of HepaFat-Scan in the management of their patients. Our immediate focus is on clinical trials for drugs under development to address fatty liver disease and Resonance Health has strong credibility working with large pharmaceutical companies for over 10 years in their global trials.

We anticipate the immediate use of HepaFat-Scan will be in a clinical trial in Australia and soon thereafter in the United States.

Extension of Closing Date of Rights Issue

Resonance Health Limited (ASX: RHT) (Resonance or the Company), in response to some shareholders not receiving or losing their entitlements form, has decided to extend the Closing Date of the entitlement offer to **5.00pm (Perth Time), Friday 6th June 2014**.

Shareholders who have not received or lost their **entitlement form** can access and obtain a copy from **Advanced Share Registry web site** at www.advanceshare.com.au selecting "Investor Login", utilizing the Shareholders' own personal **HIN/SRN**. Shareholders are encouraged to utilize the BPAY payment option as it ensures registration of acceptance.

Entitlement Offer

As announced on 10 April 2014 the non-renounceable entitlement offer will give existing eligible Resonance shareholders the opportunity to subscribe for one (1) New Share for every four (4) existing Resonance shares held at 5.00pm (AEDT) on 30 April 2014 (**Record Date**) at an Issue Price of \$0.05 per New Share. The Entitlement Offer will comprise the offer of approximately 92.7 million shares (**the Entitlement Offer Shares**) at the Issue Price to raise total proceeds of approximately \$4.6m before costs.

Shareholders may also elect to participate in the shortfall facility and apply for new shares in excess of their entitlement.

The revised timetable for the remaining dates is as follows:

Entitlement Offer Closing Date	6 June
Shares quoted on a deferred settlement basis	10 June
ASX notified of under subscriptions	10 June
Issue date/Shares entered into Shareholders' security holdings	12 June
Quotation of shares issued under the Entitlement offer	13 June

This timetable is indicative only and may be subject to change. Subject to the Corporations Act and ASX Listing Rules, Resonance reserves the right to vary the dates and times in conjunction with the Entitlement Offer, including the closing date, without prior notice.

If there is a shortfall in subscriptions under the Entitlement Offer, the Company reserves the right to place the shortfall shares at their discretion within three months of the closing date of the offer.

Azure Capital Ltd has been engaged as Lead Manager in relation to the Placement and Entitlement Offer.

For further information please contact:

Resonance Health

Adrian Bowers
Company Secretary
T: +61 8 9286 5300

E: adrianb@resonancehealth.com

Liza Dunne
Managing Director
T: +61 8 9286 5300

E: lizad@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.